MedElevator Войти в исследования
← Поиск публикаций

DOI 10.11477/mf.1436204542

Медицинская библиотека · No shinkei geka. Neurological surgery · 2022

[Molecularly Targeted Therapy for Craniopharyngioma].

Tanaka Shota, Takayanagi Shunsaku, Takami Hirokazu, Saito Nobuhito

СтатьяПеревод пока не подготовлен

Аннотация

Craniopharyngioma is a pathologically benign but clinically malignant brain tumor typically located in the parasellar region. It is treated by surgical resection, but in most cases, total removal is not amenable due to its adhesion to the adjacent vital structures, such as the optic nerve, hypothalamus, and pituitary stalk. Often, tumor regrowth or recurrence occursand it is usually treated with either re-resection or radiotherapy, including stereotactic radiosurgery. Either treatment carries some important risks, including blindness, hypopituitarism, and cognitive impairment. A recent comprehensive genomic analysis revealed that the majority of papillary craniopharyngioma cases harbor a hotspot BRAF-V600E mutation. Several case reports have illustrated dramatic response of the residual or recurrent papillary craniopharyngioma to molecularly targeted therapy with a BRAF inhibitor(vemurafenib or dabrafenib)and a MEK inhibitor(trametinib), which are currently approved for melanoma and non-small cell lung carcinoma. This medical treatment can potentially be a wonderful treatment option for papillary craniopharyngioma, given its freedom from the aforementioned serious risks associated with surgery and radiotherapy.

Для цитирования: Tanaka Shota, Takayanagi Shunsaku, Takami Hirokazu, Saito Nobuhito. [Molecularly Targeted Therapy for Craniopharyngioma].. No shinkei geka. Neurological surgery. 2022. DOI: 10.11477/mf.1436204542.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.